Registration of Patent on an immune-oncology medicine in Japan
- Patent on an immuno-oncology medicine comprising Poly I:C and LAG-3 IgG fusion protein was registered in Japan. A novel combination adjuvant based on this invention is used in CYT001, a peptide vaccine under development in Cytlimic, to boost the vaccine efficacy. read more
A phase I study for adjuvant immunotherapy has started at Yamaguchi University Graduate School of Medicine
- A phase I study (YCP002 study) of the cancer peptide vaccine CYT001 as combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma has started at Yamaguchi University Graduate School of Medicine. read more
Concluded an agreement in respect to a third-party allocation of newly issued shares
- CYTLIMIC has concluded an agreement in respect to a third-party allocation of newly issued shares to CYTLIMIC underwritten by Fast Track Initiative, Inc., SMBC Venture Capital Co., Ltd., and NEC Capital Solutions Limited as part of reinforcing its healthcare business and commencing with the drug development business.